surmount 1 tirzepatide SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Clinical trials of subcutaneous tirzepatide
Description
You are most likely to experience these issues during the initial phase of treatment or immediately after a dose increase the period when your body is adjusting to a higher level of the medication
R., Li, L., Yang, Y
The titration schedule is different
Smaller injection volumes mean less subcutaneous fluid, reduced injection site reactions, and faster absorption
